Aurora Cannabis Inc. has announced its openness to reviewing an offer from a U.S. cannabis company interested in acquiring the Edmonton-based company. The decision to form a special committee to evaluate the unsolicited bid came shortly after Curaleaf Holdings Inc. disclosed its intentions to make a bid to acquire all shares of Aurora.
If the acquisition is successful, it would result in the formation of a unified cannabis entity operating in 17 countries across Europe, North America, and other global markets, according to Curaleaf. The company, headquartered in Stamford, Connecticut, and listed on the Toronto Stock Exchange, stated that it is moving forward with its proposal publicly after unsuccessful private negotiation attempts with Aurora’s leadership.
Curaleaf mentioned that despite sending a formal letter of intent on June 23 and a follow-up letter on July 7 outlining the acquisition proposal, Aurora’s board declined to engage in discussions. Curaleaf’s CEO, Boris Jordan, expressed disappointment in Aurora’s lack of meaningful engagement and emphasized the significant premium and compelling strategic rationale behind the proposal.
The proposed offer from Curaleaf to Aurora shareholders includes $4 US per share plus an additional $0.75 US in cash for each Aurora share. Aurora confirmed the receipt of the letters from Curaleaf but disputed the claim that it rejected engagement with the offer.
Aurora clarified that its lead independent director had been in communication with Curaleaf’s CEO as recently as July 24, indicating a focus on executing its business plan in the short to medium term while remaining open to ongoing dialogue. A special committee of independent directors will now assess the proposal’s merits and potential benefits for stakeholders.
While acknowledging Curaleaf’s interest, Aurora cautioned that a deal is not guaranteed and reiterated its commitment to normal business operations in the interim. Analysts from TD Cowen expressed the view that the current offer undervalues Aurora’s long-term potential, citing the company’s market leadership in medical cannabis and strong capabilities in navigating regulatory environments.
Curaleaf’s CEO highlighted the value that could be unlocked through a merger, leveraging Curaleaf’s global distribution network with Aurora’s international medical cannabis expertise and production capacity. The combined revenue of the two companies over the past year exceeded $1.5 billion US, with Curaleaf expecting significant annual cost synergies from the proposed acquisition.
The proposed merger is seen as mutually beneficial for both Curaleaf and Aurora shareholders, offering an enhanced global platform and increased exposure to favorable U.S. regulatory trends, according to Jordan.
